直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

District Court Stays Four Cases Pending PTAB Review of CBM Patents

April 17, 2013

Authored and Edited by Jeffrey C. Totten; Jonathan R.K. Stroud

Earlier today, Judge Pearson of the Northern District of Ohio stayed four co-pending district court cases involving patents subject to a number of ongoing Covered Business Methods (CBM) Post-Grant Reviews. See Progressive Casualty Insurance Co. v. Safeco Insurance Co., No. 1:10-cv-01370, Order resolving ECF No. 98, at 22 (N.D. Ohio Apr. 17, 2013). To date, no district court has ultimately denied a motion to stay pending CBM review.

Section 18(b)(1) of the AIA specifies four factors for determining whether to stay a case pending post-grant review of CBM patents:

  1. whether a stay, or the denial thereof, will simplify the issues in question and streamline the trial;
  2. whether discovery is complete and whether a trial date has been set;
  3. whether a stay, or the denial thereof, would unduly prejudice the nonmoving party or present a clear tactical advantage for the moving party; and
  4.  whether a stay, or the denial thereof, will reduce the burden of litigation on the parties and on the court.

Judge Pearson concluded that “[t]he analysis of the four-factor test . . . counsels in favor of granting each defendant’s motion to stay” and closed each of the cases pending notification of the completion of the CBM review.

Judge Pearson considered the legislative history of the factors identified in the AIA and concluded that “the test established by the AIA is designed to increase the likelihood that a stay will be granted when transitional CBM review, in comparison with an ordinary USPTO reexamination, has been instituted.” Examining the four factors, the court concluded that factor three (undue prejudice) “moderately points in favor of denying the motions to stay, [but] it is insufficient to defeat the remaining factors which strongly counsel in favor [of] staying the cases.” The court noted that “[b]ased on the preliminary determinations made by the PTAB, it appears that each claim in contention . . . across the five patents-in-suit, is ‘more likely than not’ to be invalidated.” With respect to the fourth factor, the court found that granting a “stay would relieve Liberty Mutual and Progressive of the burden of litigating in multiple fora” and that the “Court would be relieved of having to expend substantial judicial resources in deciding claim construction, noninfringement, and invalidity issues before those claims are invalidated, narrowed, or refined through CBM review.”

 

*Jonathan R.K. Stroud is a Law Clerk at Finnegan.

Contacts

Jeffrey C. Totten
Partner
Washington, DC
+1 202 408 4232
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP